Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Prestige Consumer Healthcare's Revenue for the
three
months ended in Jun. 2026 was €230.6 Mil. Prestige Consumer Healthcare's average Accounts Receivable for the
three
months ended in Jun. 2026 was €171.5 Mil.
Hence, Prestige Consumer Healthcare's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.34.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Prestige Consumer Healthcare Receivables Turnover Related Terms
Prestige Consumer Healthcare Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PBV vs BCRX, AMLX, SUPN: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare (FRA:PBV) has a Receivables Turnover of 1.34 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Prestige Consumer Healthcare and its competitors. According to the industry distribution chart, Prestige Consumer Healthcare ranks #392 out of 946 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is Prestige Consumer Healthcare's Receivables Turnover too high?
Prestige Consumer Healthcare's current Receivables Turnover is 1.34. The Drug Manufacturers industry median Receivables Turnover is 5.10. Prestige Consumer Healthcare's value of 1.34 is 73.7% below this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #392 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's Receivables Turnover compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #392 out of 946 companies for Receivables Turnover. This puts Prestige Consumer Healthcare in the upper half of its industry. The industry median Receivables Turnover is 5.10. Prestige Consumer Healthcare's value of 1.34 is 73.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.10, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current Receivables Turnover of 1.34 is 73.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current Receivables Turnover is 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (FRA:PBV) is currently considered Modestly Undervalued. The stock's GF Value™ is €58.90, compared to a current price of €42.20 — trading 28.4% below its estimated fair value. The current Receivables Turnover is 1.34 and 73.7% below the Drug Manufacturers industry median of 5.10. Prestige Consumer Healthcare's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Prestige Consumer Healthcare (FRA:PBV), the current Receivables Turnover is 1.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (FRA:PBV) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of €42.20 is trading 28.4% below its estimated GF Value™ of €58.90.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for FRA:PBV:
Receivables Turnover: 1.34
GF Value™: €58.90 vs. price of €42.20 (28.4% below fair value)
Industry Position: 73.7% below the Drug Manufacturers median (#392 of 946)
No single metric tells the full story. See the FRA:PBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
68GF Score
Get the complete analysis for FRA:PBV
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PBV has been successfully added to your 
